June 20th, 2019

BioVersys announces a EUR 6.92 Million funding of its TRIC-TB project by the IMI2 JU

BioVersys is pleased to announce that it has received an IMI2 JU grant of 6.92 million EUR to fund further preclinical through to first clinical development of candidate molecules from the TRIC-TB project which have been developed in a successful collaboration with GSK, the Institut Pasteur de Lille and University of Lille (with groups of Nicolas Willand, Alain Baulard and Benoit Deprez). The project previously received valuable financial support from the Wellcome Trust.

PDF here

http://c1940652.r52.cf0.rackcdn.com/58528159b8d39a3eff000d0c/news1.jpg